Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8691460rdf:typepubmed:Citationlld:pubmed
pubmed-article:8691460lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:8691460lifeskim:mentionsumls-concept:C0001407lld:lifeskim
pubmed-article:8691460lifeskim:mentionsumls-concept:C0028621lld:lifeskim
pubmed-article:8691460lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:8691460lifeskim:mentionsumls-concept:C1819464lld:lifeskim
pubmed-article:8691460lifeskim:mentionsumls-concept:C0376211lld:lifeskim
pubmed-article:8691460lifeskim:mentionsumls-concept:C0243077lld:lifeskim
pubmed-article:8691460pubmed:issue13lld:pubmed
pubmed-article:8691460pubmed:dateCreated1996-8-23lld:pubmed
pubmed-article:8691460pubmed:abstractTextA series of four structurally related carbocyclic nucleosides (6a, 6b, 10a, and 10b) were synthesized and evaluated for their ability to inhibit tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), and interleukin-6 (IL-6) production from human primary macrophages. These compounds had little effect on the production of IL-1 beta and IL-6. It was determined that compound 10a was the most potent inhibitor of TNF-alpha production (IC50 = 10 microM), having 2-5-fold more activity compared to its enantiomer 10b or its diastereomers 6a and 6b. In addition, these compounds were also tested for their ability to protect mice against lethal challenges of lipopolysaccharide (LPS) and D-galactosamine (D-Gal). Compound 10a showed superior protective effects (100% protection) compared to its enantiomer 10b or its diastereomers 6a and 6b when it was administered to mice which were challenged with 3 times the LD100 dose of LPS.lld:pubmed
pubmed-article:8691460pubmed:languageenglld:pubmed
pubmed-article:8691460pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8691460pubmed:citationSubsetIMlld:pubmed
pubmed-article:8691460pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8691460pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8691460pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8691460pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8691460pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8691460pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8691460pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8691460pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8691460pubmed:statusMEDLINElld:pubmed
pubmed-article:8691460pubmed:monthJunlld:pubmed
pubmed-article:8691460pubmed:issn0022-2623lld:pubmed
pubmed-article:8691460pubmed:authorpubmed-author:HoffmanP FPFlld:pubmed
pubmed-article:8691460pubmed:authorpubmed-author:ZhangHHlld:pubmed
pubmed-article:8691460pubmed:authorpubmed-author:EdwardsC...lld:pubmed
pubmed-article:8691460pubmed:authorpubmed-author:BowlinT LTLlld:pubmed
pubmed-article:8691460pubmed:authorpubmed-author:MONKC BCBlld:pubmed
pubmed-article:8691460pubmed:authorpubmed-author:BorcherdingD...lld:pubmed
pubmed-article:8691460pubmed:authorpubmed-author:MunsonH RHRlld:pubmed
pubmed-article:8691460pubmed:issnTypePrintlld:pubmed
pubmed-article:8691460pubmed:day21lld:pubmed
pubmed-article:8691460pubmed:volume39lld:pubmed
pubmed-article:8691460pubmed:ownerNLMlld:pubmed
pubmed-article:8691460pubmed:authorsCompleteYlld:pubmed
pubmed-article:8691460pubmed:pagination2615-20lld:pubmed
pubmed-article:8691460pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:8691460pubmed:meshHeadingpubmed-meshheading:8691460-...lld:pubmed
pubmed-article:8691460pubmed:meshHeadingpubmed-meshheading:8691460-...lld:pubmed
pubmed-article:8691460pubmed:meshHeadingpubmed-meshheading:8691460-...lld:pubmed
pubmed-article:8691460pubmed:meshHeadingpubmed-meshheading:8691460-...lld:pubmed
pubmed-article:8691460pubmed:meshHeadingpubmed-meshheading:8691460-...lld:pubmed
pubmed-article:8691460pubmed:meshHeadingpubmed-meshheading:8691460-...lld:pubmed
pubmed-article:8691460pubmed:meshHeadingpubmed-meshheading:8691460-...lld:pubmed
pubmed-article:8691460pubmed:meshHeadingpubmed-meshheading:8691460-...lld:pubmed
pubmed-article:8691460pubmed:meshHeadingpubmed-meshheading:8691460-...lld:pubmed
pubmed-article:8691460pubmed:meshHeadingpubmed-meshheading:8691460-...lld:pubmed
pubmed-article:8691460pubmed:meshHeadingpubmed-meshheading:8691460-...lld:pubmed
pubmed-article:8691460pubmed:meshHeadingpubmed-meshheading:8691460-...lld:pubmed
pubmed-article:8691460pubmed:meshHeadingpubmed-meshheading:8691460-...lld:pubmed
pubmed-article:8691460pubmed:meshHeadingpubmed-meshheading:8691460-...lld:pubmed
pubmed-article:8691460pubmed:meshHeadingpubmed-meshheading:8691460-...lld:pubmed
pubmed-article:8691460pubmed:year1996lld:pubmed
pubmed-article:8691460pubmed:articleTitleCarbocyclic nucleosides as inhibitors of human tumor necrosis factor-alpha production: effects of the stereoisomers of (3-hydroxycyclopentyl)adenines.lld:pubmed
pubmed-article:8691460pubmed:affiliationHoechst Marion Roussel, Inc., Cincinnati, Ohio 45215-6300, USA.lld:pubmed
pubmed-article:8691460pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:8691460lld:chembl